Aegerion Pharmaceuticals Inc., a Bridgewater, N.J.-based drug developer focused on cardiovascular and metabolic diseases, has re-filed for an $86.25 million IPO. This the the company’s third IPO filing, having twice before filed and withdrawn due to “market conditions.”
Leerink Swan and Lazard Capital Markets are serving as co-lead underwriters.
Aegerion has raised over $44 million in total VC funding, from firms like Index Ventures, Advent International, Alta Partners, Scheer & Co. and MVM Life Science Partners. www.aegerion.com